Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 91

1.

Circulating cytokines predict immune-related toxicity in melanoma patients receiving anti-PD-1-based immunotherapy.

Lim SY, Lee JH, Gide TN, Menzies AM, Guminski A, Carlino MS, Breen EJ, Yang JYH, Ghazanfar S, Kefford RF, Scolyer RA, Long GV, Rizos H.

Clin Cancer Res. 2018 Nov 8. pii: clincanres.2795.2018. doi: 10.1158/1078-0432.CCR-18-2795. [Epub ahead of print]

PMID:
30409824
2.

Monitoring Melanoma Using Circulating Free DNA.

Diefenbach RJ, Lee JH, Rizos H.

Am J Clin Dermatol. 2018 Oct 29. doi: 10.1007/s40257-018-0398-x. [Epub ahead of print]

PMID:
30374893
3.

Oncogenic PI3K/AKT promotes the step-wise evolution of combination BRAF/MEK inhibitor resistance in melanoma.

Irvine M, Stewart A, Pedersen B, Boyd S, Kefford R, Rizos H.

Oncogenesis. 2018 Sep 20;7(9):72. doi: 10.1038/s41389-018-0081-3.

4.

Interferon Signaling Is Frequently Downregulated in Melanoma.

Alavi S, Stewart AJ, Kefford RF, Lim SY, Shklovskaya E, Rizos H.

Front Immunol. 2018 Jun 21;9:1414. doi: 10.3389/fimmu.2018.01414. eCollection 2018.

5.

Immune cell profiling in the age of immune checkpoint inhibitors: implications for biomarker discovery and understanding of resistance mechanisms.

Lim SY, Rizos H.

Mamm Genome. 2018 Dec;29(11-12):866-878. doi: 10.1007/s00335-018-9757-4. Epub 2018 Jul 2. Review.

PMID:
29968076
6.

Oncogenic signaling in uveal melanoma.

Park JJ, Diefenbach RJ, Joshua AM, Kefford RF, Carlino MS, Rizos H.

Pigment Cell Melanoma Res. 2018 Nov;31(6):661-672. doi: 10.1111/pcmr.12708. Epub 2018 May 23. Review.

PMID:
29738114
7.

Association Between Circulating Tumor DNA and Pseudoprogression in Patients With Metastatic Melanoma Treated With Anti-Programmed Cell Death 1 Antibodies.

Lee JH, Long GV, Menzies AM, Lo S, Guminski A, Whitbourne K, Peranec M, Scolyer R, Kefford RF, Rizos H, Carlino MS.

JAMA Oncol. 2018 May 1;4(5):717-721. doi: 10.1001/jamaoncol.2017.5332.

PMID:
29423503
8.

Liquid biomarkers in melanoma: detection and discovery.

Lim SY, Lee JH, Diefenbach RJ, Kefford RF, Rizos H.

Mol Cancer. 2018 Jan 17;17(1):8. doi: 10.1186/s12943-018-0757-5. Review.

9.

HDAC inhibitors restore BRAF-inhibitor sensitivity by altering PI3K and survival signalling in a subset of melanoma.

Gallagher SJ, Gunatilake D, Beaumont KA, Sharp DM, Tiffen JC, Heinemann A, Weninger W, Haass NK, Wilmott JS, Madore J, Ferguson PM, Rizos H, Hersey P.

Int J Cancer. 2018 May 1;142(9):1926-1937. doi: 10.1002/ijc.31199. Epub 2017 Dec 20.

PMID:
29210065
10.

Evaluation of two high-throughput proteomic technologies for plasma biomarker discovery in immunotherapy-treated melanoma patients.

Lim SY, Lee JH, Welsh SJ, Ahn SB, Breen E, Khan A, Carlino MS, Menzies AM, Kefford RF, Scolyer RA, Long GV, Rizos H.

Biomark Res. 2017 Nov 10;5:32. doi: 10.1186/s40364-017-0112-9. eCollection 2017.

11.

PD-L1 Expression and Immune Escape in Melanoma Resistance to MAPK Inhibitors.

Kakavand H, Rawson RV, Pupo GM, Yang JYH, Menzies AM, Carlino MS, Kefford RF, Howle JR, Saw RPM, Thompson JF, Wilmott JS, Long GV, Scolyer RA, Rizos H.

Clin Cancer Res. 2017 Oct 15;23(20):6054-6061. doi: 10.1158/1078-0432.CCR-16-1688. Epub 2017 Jul 19.

12.

EIF1AX and NRAS Mutations Co-occur and Cooperate in Low-Grade Serous Ovarian Carcinomas.

Etemadmoghadam D, Azar WJ, Lei Y, Moujaber T, Garsed DW, Kennedy CJ, Fereday S, Mitchell C, Chiew YE, Hendley J, Sharma R, Harnett PR, Li J, Christie EL, Patch AM, George J, Au-Yeung G, Mir Arnau G, Holloway TP, Semple T, Pearson JV, Waddell N, Grimmond SM, Köbel M, Rizos H, Lomakin IB, Bowtell DDL, deFazio A; Australian Ovarian Cancer Study Group.

Cancer Res. 2017 Aug 15;77(16):4268-4278. doi: 10.1158/0008-5472.CAN-16-2224. Epub 2017 Jun 23.

13.

Mechanisms and strategies to overcome resistance to molecularly targeted therapy for melanoma.

Lim SY, Menzies AM, Rizos H.

Cancer. 2017 Jun 1;123(S11):2118-2129. doi: 10.1002/cncr.30435. Review.

14.

Clinical significance of intronic variants in BRAF inhibitor resistant melanomas with altered BRAF transcript splicing.

Pupo GM, Boyd SC, Fung C, Carlino MS, Menzies AM, Pedersen B, Johansson P, Hayward NK, Kefford RF, Scolyer RA, Long GV, Rizos H.

Biomark Res. 2017 May 11;5:17. doi: 10.1186/s40364-017-0098-3. eCollection 2017.

15.

The "Tricky Business" of Identifying Mechanisms of Resistance to Anti-PD-1.

Wilmott JS, Rizos H, Scolyer RA, Long GV.

Clin Cancer Res. 2017 Jun 15;23(12):2921-2923. doi: 10.1158/1078-0432.CCR-17-0669. Epub 2017 May 3.

16.

Biomarker Accessible and Chemically Addressable Mechanistic Subtypes of BRAF Melanoma.

Eskiocak B, McMillan EA, Mendiratta S, Kollipara RK, Zhang H, Humphries CG, Wang C, Garcia-Rodriguez J, Ding M, Zaman A, Rosales TI, Eskiocak U, Smith MP, Sudderth J, Komurov K, Deberardinis RJ, Wellbrock C, Davies MA, Wargo JA, Yu Y, De Brabander JK, Williams NS, Chin L, Rizos H, Long GV, Kittler R, White MA.

Cancer Discov. 2017 Aug;7(8):832-851. doi: 10.1158/2159-8290.CD-16-0955. Epub 2017 Apr 28.

17.

Circulating tumour DNA predicts response to anti-PD1 antibodies in metastatic melanoma.

Lee JH, Long GV, Boyd S, Lo S, Menzies AM, Tembe V, Guminski A, Jakrot V, Scolyer RA, Mann GJ, Kefford RF, Carlino MS, Rizos H.

Ann Oncol. 2017 May 1;28(5):1130-1136. doi: 10.1093/annonc/mdx026.

PMID:
28327969
18.

The Role of Sumoylation in Senescence.

Scurr LL, Haferkamp S, Rizos H.

Adv Exp Med Biol. 2017;963:215-226. doi: 10.1007/978-3-319-50044-7_13. Review.

PMID:
28197915
19.

Resistance to combination BRAF and MEK inhibition in metastatic melanoma: Where to next?

Welsh SJ, Rizos H, Scolyer RA, Long GV.

Eur J Cancer. 2016 Jul;62:76-85. doi: 10.1016/j.ejca.2016.04.005. Epub 2016 May 24. Review.

PMID:
27232329
20.

Melanocyte reprogramming requires chromatin and transcription remodelling.

Welsh SJ, Rizos H.

Pigment Cell Melanoma Res. 2016 May;29(3):260-1. doi: 10.1111/pcmr.12457. Epub 2016 Mar 3. No abstract available.

PMID:
26813636
21.

Acquired BRAF inhibitor resistance: A multicenter meta-analysis of the spectrum and frequencies, clinical behaviour, and phenotypic associations of resistance mechanisms.

Johnson DB, Menzies AM, Zimmer L, Eroglu Z, Ye F, Zhao S, Rizos H, Sucker A, Scolyer RA, Gutzmer R, Gogas H, Kefford RF, Thompson JF, Becker JC, Berking C, Egberts F, Loquai C, Goldinger SM, Pupo GM, Hugo W, Kong X, Garraway LA, Sosman JA, Ribas A, Lo RS, Long GV, Schadendorf D.

Eur J Cancer. 2015 Dec;51(18):2792-9. doi: 10.1016/j.ejca.2015.08.022. Epub 2015 Nov 19.

22.

Circulating tumor DNA to monitor treatment response and detect acquired resistance in patients with metastatic melanoma.

Gray ES, Rizos H, Reid AL, Boyd SC, Pereira MR, Lo J, Tembe V, Freeman J, Lee JH, Scolyer RA, Siew K, Lomma C, Cooper A, Khattak MA, Meniawy TM, Long GV, Carlino MS, Millward M, Ziman M.

Oncotarget. 2015 Dec 8;6(39):42008-18. doi: 10.18632/oncotarget.5788.

23.

Targeting oncogenic BRAF and aberrant MAPK activation in the treatment of cutaneous melanoma.

Carlino MS, Long GV, Kefford RF, Rizos H.

Crit Rev Oncol Hematol. 2015 Dec;96(3):385-98. doi: 10.1016/j.critrevonc.2015.08.021. Epub 2015 Aug 28. Review.

PMID:
26358420
24.

The transcription cofactor c-JUN mediates phenotype switching and BRAF inhibitor resistance in melanoma.

Ramsdale R, Jorissen RN, Li FZ, Al-Obaidi S, Ward T, Sheppard KE, Bukczynska PE, Young RJ, Boyle SE, Shackleton M, Bollag G, Long GV, Tulchinsky E, Rizos H, Pearson RB, McArthur GA, Dhillon AS, Ferrao PT.

Sci Signal. 2015 Aug 18;8(390):ra82. doi: 10.1126/scisignal.aab1111.

PMID:
26286024
25.

The BARD1 BRCT domain contributes to p53 binding, cytoplasmic and mitochondrial localization, and apoptotic function.

Tembe V, Martino-Echarri E, Marzec KA, Mok MT, Brodie KM, Mills K, Lei Y, DeFazio A, Rizos H, Kettle E, Boadle R, Henderson BR.

Cell Signal. 2015 Sep;27(9):1763-71. doi: 10.1016/j.cellsig.2015.05.011. Epub 2015 Jun 3.

PMID:
26022179
26.

Inducible but not constitutive expression of PD-L1 in human melanoma cells is dependent on activation of NF-κB.

Gowrishankar K, Gunatilake D, Gallagher SJ, Tiffen J, Rizos H, Hersey P.

PLoS One. 2015 Apr 6;10(4):e0123410. doi: 10.1371/journal.pone.0123410. eCollection 2015.

27.

Resistance to c-Kit inhibitors in melanoma: insights for future therapies.

Carlino MS, Todd JR, Rizos H.

Oncoscience. 2014 Jun 6;1(6):423-6. eCollection 2014.

28.

Oncolytic virotherapy using herpes simplex virus: how far have we come?

Sokolowski NA, Rizos H, Diefenbach RJ.

Oncolytic Virother. 2015 Nov 25;4:207-19. doi: 10.2147/OV.S66086. eCollection 2015. Review.

29.

Increased MAPK reactivation in early resistance to dabrafenib/trametinib combination therapy of BRAF-mutant metastatic melanoma.

Long GV, Fung C, Menzies AM, Pupo GM, Carlino MS, Hyman J, Shahheydari H, Tembe V, Thompson JF, Saw RP, Howle J, Hayward NK, Johansson P, Scolyer RA, Kefford RF, Rizos H.

Nat Commun. 2014 Dec 2;5:5694. doi: 10.1038/ncomms6694.

PMID:
25452114
30.

Preexisting MEK1P124 mutations diminish response to BRAF inhibitors in metastatic melanoma patients.

Carlino MS, Fung C, Shahheydari H, Todd JR, Boyd SC, Irvine M, Nagrial AM, Scolyer RA, Kefford RF, Long GV, Rizos H.

Clin Cancer Res. 2015 Jan 1;21(1):98-105. doi: 10.1158/1078-0432.CCR-14-0759. Epub 2014 Nov 4.

31.

Inhibition of mTORC1/2 overcomes resistance to MAPK pathway inhibitors mediated by PGC1α and oxidative phosphorylation in melanoma.

Gopal YN, Rizos H, Chen G, Deng W, Frederick DT, Cooper ZA, Scolyer RA, Pupo G, Komurov K, Sehgal V, Zhang J, Patel L, Pereira CG, Broom BM, Mills GB, Ram P, Smith PD, Wargo JA, Long GV, Davies MA.

Cancer Res. 2014 Dec 1;74(23):7037-47. doi: 10.1158/0008-5472.CAN-14-1392. Epub 2014 Oct 8.

32.

Silencer of death domains controls cell death through tumour necrosis factor-receptor 1 and caspase-10 in acute lymphoblastic leukemia.

Cisterne A, Baraz R, Khan NI, Welschinger R, Basnett J, Fung C, Rizos H, Bradstock KF, Bendall LJ.

PLoS One. 2014 Jul 25;9(7):e103383. doi: 10.1371/journal.pone.0103383. eCollection 2014.

33.

Control of NF-kB activity in human melanoma by bromodomain and extra-terminal protein inhibitor I-BET151.

Gallagher SJ, Mijatov B, Gunatilake D, Gowrishankar K, Tiffen J, James W, Jin L, Pupo G, Cullinane C, McArthur GA, Tummino PJ, Rizos H, Hersey P.

Pigment Cell Melanoma Res. 2014 Nov;27(6):1126-37. doi: 10.1111/pcmr.12282. Epub 2014 Jul 3.

PMID:
24924589
34.

The epigenetic regulator I-BET151 induces BIM-dependent apoptosis and cell cycle arrest of human melanoma cells.

Gallagher SJ, Mijatov B, Gunatilake D, Tiffen JC, Gowrishankar K, Jin L, Pupo GM, Cullinane C, Prinjha RK, Smithers N, McArthur GA, Rizos H, Hersey P.

J Invest Dermatol. 2014 Nov;134(11):2795-2805. doi: 10.1038/jid.2014.243. Epub 2014 Jun 6.

35.

WNT5A enhances resistance of melanoma cells to targeted BRAF inhibitors.

Anastas JN, Kulikauskas RM, Tamir T, Rizos H, Long GV, von Euw EM, Yang PT, Chen HW, Haydu L, Toroni RA, Lucero OM, Chien AJ, Moon RT.

J Clin Invest. 2014 Jul;124(7):2877-90. doi: 10.1172/JCI70156. Epub 2014 May 27.

36.

Targeted BRAF inhibition impacts survival in melanoma patients with high levels of Wnt/β-catenin signaling.

Chien AJ, Haydu LE, Biechele TL, Kulikauskas RM, Rizos H, Kefford RF, Scolyer RA, Moon RT, Long GV.

PLoS One. 2014 Apr 14;9(4):e94748. doi: 10.1371/journal.pone.0094748. eCollection 2014.

37.

Differential activity of MEK and ERK inhibitors in BRAF inhibitor resistant melanoma.

Carlino MS, Todd JR, Gowrishankar K, Mijatov B, Pupo GM, Fung C, Snoyman S, Hersey P, Long GV, Kefford RF, Rizos H.

Mol Oncol. 2014 May;8(3):544-54. doi: 10.1016/j.molonc.2014.01.003. Epub 2014 Jan 15.

38.

Response of BRAF-mutant melanoma to BRAF inhibition is mediated by a network of transcriptional regulators of glycolysis.

Parmenter TJ, Kleinschmidt M, Kinross KM, Bond ST, Li J, Kaadige MR, Rao A, Sheppard KE, Hugo W, Pupo GM, Pearson RB, McGee SL, Long GV, Scolyer RA, Rizos H, Lo RS, Cullinane C, Ayer DE, Ribas A, Johnstone RW, Hicks RJ, McArthur GA.

Cancer Discov. 2014 Apr;4(4):423-33. doi: 10.1158/2159-8290.CD-13-0440. Epub 2014 Jan 27.

39.

BRAF inhibitor resistance mechanisms in metastatic melanoma: spectrum and clinical impact.

Rizos H, Menzies AM, Pupo GM, Carlino MS, Fung C, Hyman J, Haydu LE, Mijatov B, Becker TM, Boyd SC, Howle J, Saw R, Thompson JF, Kefford RF, Scolyer RA, Long GV.

Clin Cancer Res. 2014 Apr 1;20(7):1965-77. doi: 10.1158/1078-0432.CCR-13-3122. Epub 2014 Jan 24.

40.

Oncogenic activation of MEK/ERK primes melanoma cells for adaptation to endoplasmic reticulum stress.

Croft A, Tay KH, Boyd SC, Guo ST, Jiang CC, Lai F, Tseng HY, Jin L, Rizos H, Hersey P, Zhang XD.

J Invest Dermatol. 2014 Feb;134(2):488-497. doi: 10.1038/jid.2013.325. Epub 2013 Aug 6.

41.

Antiproliferative effects of continued mitogen-activated protein kinase pathway inhibition following acquired resistance to BRAF and/or MEK inhibition in melanoma.

Carlino MS, Gowrishankar K, Saunders CA, Pupo GM, Snoyman S, Zhang XD, Saw R, Becker TM, Kefford RF, Long GV, Rizos H.

Mol Cancer Ther. 2013 Jul;12(7):1332-42. doi: 10.1158/1535-7163.MCT-13-0011. Epub 2013 May 3.

42.

Secondary c-Kit mutations confer acquired resistance to RTK inhibitors in c-Kit mutant melanoma cells.

Todd JR, Becker TM, Kefford RF, Rizos H.

Pigment Cell Melanoma Res. 2013 Jul;26(4):518-26. doi: 10.1111/pcmr.12107. Epub 2013 May 13.

PMID:
23582185
43.

Effects of BRAF inhibitors on human melanoma tissue before treatment, early during treatment, and on progression.

Long GV, Wilmott JS, Haydu LE, Tembe V, Sharma R, Rizos H, Thompson JF, Howle J, Scolyer RA, Kefford RF.

Pigment Cell Melanoma Res. 2013 Jul;26(4):499-508. doi: 10.1111/pcmr.12098. Epub 2013 May 3.

PMID:
23557327
44.

Human nevi lack distinguishing senescence traits.

Tran S, Rizos H.

Aging (Albany NY). 2013 Feb;5(2):98-9. No abstract available.

PMID:
23518674
Free PMC Article
45.

Mutant B-RAF-Mcl-1 survival signaling depends on the STAT3 transcription factor.

Becker TM, Boyd SC, Mijatov B, Gowrishankar K, Snoyman S, Pupo GM, Scolyer RA, Mann GJ, Kefford RF, Zhang XD, Rizos H.

Oncogene. 2014 Feb 27;33(9):1158-66. doi: 10.1038/onc.2013.45. Epub 2013 Mar 4.

PMID:
23455323
46.

PI(4,5)P2 5-phosphatase A regulates PI3K/Akt signalling and has a tumour suppressive role in human melanoma.

Ye Y, Jin L, Wilmott JS, Hu WL, Yosufi B, Thorne RF, Liu T, Rizos H, Yan XG, Dong L, Tay KH, Tseng HY, Guo ST, de Bock CE, Jiang CC, Wang CY, Wu M, Zhang LJ, Hersey P, Scolyer RA, Zhang XD.

Nat Commun. 2013;4:1508. doi: 10.1038/ncomms2489.

47.

Monitoring oncogenic B-RAF-induced senescence in melanocytes.

Tran SL, Rizos H.

Methods Mol Biol. 2013;965:313-26. doi: 10.1007/978-1-62703-239-1_21.

PMID:
23296668
48.

p16(INK) (4a) deficiency promotes DNA hyper-replication and genetic instability in melanocytes.

Fung C, Pupo GM, Scolyer RA, Kefford RF, Rizos H.

Pigment Cell Melanoma Res. 2013 Mar;26(2):236-46. doi: 10.1111/pcmr.12062. Epub 2013 Jan 24.

PMID:
23279822
49.

The MAPK pathway functions as a redundant survival signal that reinforces the PI3K cascade in c-Kit mutant melanoma.

Todd JR, Scurr LL, Becker TM, Kefford RF, Rizos H.

Oncogene. 2014 Jan 9;33(2):236-45. doi: 10.1038/onc.2012.562. Epub 2012 Dec 17.

PMID:
23246970
50.

Oncogenic B-RAF(V600E) signaling induces the T-Box3 transcriptional repressor to repress E-cadherin and enhance melanoma cell invasion.

Boyd SC, Mijatov B, Pupo GM, Tran SL, Gowrishankar K, Shaw HM, Goding CR, Scolyer RA, Mann GJ, Kefford RF, Rizos H, Becker TM.

J Invest Dermatol. 2013 May;133(5):1269-77. doi: 10.1038/jid.2012.421. Epub 2012 Nov 29.

Supplemental Content

Support Center